Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewA 68930 hydrochloride is a potent and selective D1-like dopamine receptor agonist (EC50 values are 2.1 and 3910 nM for D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.
分子量 | 307.78 |
公式 | C16H17NO3.HCl |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 130465-39-3 |
PubChem ID | 9904672 |
InChI Key | PQPGUUQPTSMLKU-YYLIZZNMSA-N |
Smiles | OC1=C(O)C=CC2=C1C[C@@H]([C@]3=CC=CC=C3)O[C@H]2CN.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 15.39 | 50 |
以下数据基于产品分子量 307.78。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.5 mM | 6.5 mL | 32.49 mL | 64.98 mL |
2.5 mM | 1.3 mL | 6.5 mL | 13 mL |
5 mM | 0.65 mL | 3.25 mL | 6.5 mL |
25 mM | 0.13 mL | 0.65 mL | 1.3 mL |
参考文献是支持产品生物活性的出版物。
Deveney and Waddingto (1997) Psychopharmacological distinction between novel full-efficacy "D1-like" DA receptor agonists. Pharmacol.Biochem.Behav. 58 551 PMID: 9300618
Kebabian et al (1990) A68930: a potent and specific agonist for the D-1 DA receptor. Am.J.Hypertens. 3 40S PMID: 2143387
Quaglia et al (1990) (1R,3S)-1-(Aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J.Med.Chem. 33 2948 PMID: 1977907
If you know of a relevant reference for A 68930 hydrochloride, please let us know.
关键词: A 68930 hydrochloride, A 68930 hydrochloride supplier, Potent, selective, D1-like, agonists, Dopamine, D1, Receptors, D5, dopaminergic, A68930, hydrochloride, and, 1534, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 A 68930 hydrochloride 的部分引用包括:
Guha et al (2012) Stimulation of the D5 DA receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and decreases accumulation of autofluorescent photoreceptor debris. J Neurochem 122 823 PMID: 22639870
Blasic et al (2012) Phosphorylation of mouse melanopsin by protein kinase A. Sci Rep 7 e45387 PMID: 23049792
Mizuta et al (2013) The DA D1 receptor is expressed and facilitates relaxation in airway smooth muscle. PLoS One 14 89 PMID: 24004608
您是否知道使用了 Tocris A 68930 hydrochloride 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review A 68930 hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.